| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Cyclin-dependent kinase 9 |
|---|
| Ligand | BDBM81440 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | In Vitro Kinase Assay |
|---|
| Ki | 5.9±3.3 nM |
|---|
| Citation |  Wang, S; Griffiths, G; Midgley, CA; Barnett, AL; Cooper, M; Grabarek, J; Ingram, L; Jackson, W; Kontopidis, G; McClue, SJ; McInnes, C; McLachlan, J; Meades, C; Mezna, M; Stuart, I; Thomas, MP; Zheleva, DI; Lane, DP; Jackson, RC; Glover, DM; Blake, DG; Fischer, PM Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. Chem Biol17:1111-21 (2010) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Cyclin-dependent kinase 9 |
|---|
| Name: | Cyclin-dependent kinase 9 |
|---|
| Synonyms: | C-2K | CDC2L4 | CDK9 | CDK9_HUMAN | Cell division cycle 2-like protein kinase 4 | Cell division protein kinase 9 | Cyclin-Dependent Kinase 9 (CDK9) | Cyclin-dependent kinase 9 (CDK9) | Serine/threonine-protein kinase PITALRE | TAK | Tat-associated kinase complex catalytic subunit |
|---|
| Type: | Enzyme Subunit |
|---|
| Mol. Mass.: | 42789.13 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | n/a |
|---|
| Residue: | 372 |
|---|
| Sequence: | MAKQYDSVECPFCDEVSKYEKLAKIGQGTFGEVFKARHRKTGQKVALKKVLMENEKEGFP
ITALREIKILQLLKHENVVNLIEICRTKASPYNRCKGSIYLVFDFCEHDLAGLLSNVLVK
FTLSEIKRVMQMLLNGLYYIHRNKILHRDMKAANVLITRDGVLKLADFGLARAFSLAKNS
QPNRYTNRVVTLWYRPPELLLGERDYGPPIDLWGAGCIMAEMWTRSPIMQGNTEQHQLAL
ISQLCGSITPEVWPNVDNYELYEKLELVKGQKRKVKDRLKAYVRDPYALDLIDKLLVLDP
AQRIDSDDALNHDFFWSDPMPSDLKGMLSTHLTSMFEYLAPPRRKGSQITQQSTNQSRNP
ATTNQTEFERVF
|
|
|
|---|
| BDBM81440 |
|---|
| n/a |
|---|
| Name | BDBM81440 |
|---|
| Synonyms: | CDK Inhibitor, 13 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C16H15N5O3S |
|---|
| Mol. Mass. | 357.387 |
|---|
| SMILES | Cc1c(sc(=O)n1C)-c1ccnc(Nc2ccc(C)c(c2)N(=O)=O)n1 |
|---|
| Structure | 
|
|---|
Search and Browse
